Eliyahou Et Al Harari Acquires 1,757,469 Shares of CapsoVision (NASDAQ:CV) Stock

Posted by George Bondi on Sep 23rd, 2026

CapsoVision, Inc. (NASDAQ:CV – Get Free Report) major shareholder Eliyahou Et Al Harari bought 1,757,469 shares of the stock in a transaction dated Friday, September 18th. The shares were acquired at an average price of $5.69 per share, for a total transaction of $9,999,998.61. Following the completion of the purchase, the insider directly owned 1,396,494 shares in the company, valued at approximately $7,946,050.86. This trade represents a -486.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Eliyahou Et Al Harari also recently made the following trade(s):

On Friday, July 17th, Eliyahou Et Al Harari acquired 61,068 shares of CapsoVision stock. The stock was purchased at an average price of $6.73 per share, with a total value of $410,987.64.
On Wednesday, July 8th, Eliyahou Et Al Harari purchased 81,300 shares of CapsoVision stock. The stock was bought at an average cost of $6.09 per share, for a total transaction of $495,117.00.
On Friday, June 26th, Eliyahou Et Al Harari purchased 13,850 shares of CapsoVision stock. The stock was acquired at an average cost of $7.35 per share, with a total value of $101,797.50.

CapsoVision Stock Down 4.0%

Shares of NASDAQ:CV traded down $0.25 during midday trading on Wednesday, reaching $6.05. The company’s stock had a trading volume of 443,201 shares, compared to its average volume of 232,631. CapsoVision, Inc. has a 12-month low of $4.34 and a 12-month high of $15.37. The firm has a 50 day moving average of $6.41 and a 200-day moving average of $6.55. The firm has a market capitalization of $302.78 million, a P/E ratio of -12.87 and a beta of -2.47.

CapsoVision (NASDAQ:CV – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.15) earnings per share for the quarter. The firm had revenue of $3.64 million for the quarter. CapsoVision had a negative net margin of 214.74% and a negative return on equity of 177.85%. On average, research analysts predict that CapsoVision, Inc. will post -0.56 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on CV shares. Zacks Research raised shares of CapsoVision to a “hold” rating in a research report on Monday, August 31st. Benchmark reaffirmed a “speculative buy” rating on shares of CapsoVision in a research note on Friday, August 14th. Roth Capital began coverage on shares of CapsoVision in a report on Friday, August 28th. They set a “buy” rating and a $9.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CapsoVision in a research report on Monday, June 29th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, CapsoVision currently has an average rating of “Hold” and an average target price of $9.50.

Read Our Latest Analysis on CV

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CV. BlackRock Inc. acquired a new position in shares of CapsoVision during the 2nd quarter worth approximately $14,372,000. Bank of America Corp DE bought a new stake in shares of CapsoVision during the 2nd quarter valued at approximately $193,000. Bank of New York Mellon Corp acquired a new position in CapsoVision in the 2nd quarter worth about $569,000. Connective Capital Management LLC bought a new stake in CapsoVision during the 2nd quarter worth approximately $76,000. Finally, Legal & General Group Plc bought a new position in CapsoVision during the 2nd quarter worth $26,000.

CapsoVision Company Profile

(Get Free Report)

CapsoVision, Inc is a medical technology company focused on developing and commercializing capsule endoscopy systems for gastrointestinal (GI) diagnostics. Its products are designed to help physicians examine the digestive tract, particularly the small intestine, using an ingestible capsule rather than a conventional endoscopic procedure.

The company’s principal product is CapsoCam Plus, an ingestible capsule endoscope that captures panoramic images as it travels through the gastrointestinal tract.